All Relations between asymmetrical (pato 0000616) and nitrogen monoxide

Reference Sentence Publish Date Extraction Date Species
Phillip E Gates, Meghan L Boucher, Annemarie E Silver, Kevin D Monahan, Douglas R Seal. Impaired flow-mediated dilation with age is not explained by L-arginine bioavailability or endothelial asymmetric dimethylarginine protein expression. Journal of applied physiology (Bethesda, Md. : 1985) vol 102 issue 1 2007 16946027 impaired fmd may be mediated in part by a decrease in synthesis of nitric oxide by endothelial nitric oxide synthase, and in clinical populations this has been attributed to competitive inhibition of l-arginine binding sites by asymmetric dimethylarginine (adma). 2007-03-13 2022-01-12 Not clear
Usman Khan, Ahamad Hassan, Patrick Vallance, Hugh S Marku. Asymmetric dimethylarginine in cerebral small vessel disease. Stroke vol 38 issue 2 2007 17204687 asymmetric dimethylarginine (adma), a circulating endogenous inhibitor of nitric oxide, has been implicated in endothelial dysfunction, particularly in hyperhomocystinemia, a known risk factor for svd. 2007-03-12 2022-01-12 Not clear
S Aslam, T Santha, A Leone, C Wilco. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney international vol 70 issue 12 2007 17063175 we tested the hypothesis that therapy with valsartan, an angiotensin receptor blocker and amlodipine, an antioxidant calcium channel blocker will reduce oxidative stress and the plasma levels of asymmetric dimethylarginine (adma), an endogenous inhibitor of nitric oxide synthase. 2007-02-28 2022-01-12 Not clear
C Zoccal. Asymmetric dimethylarginine in end-stage renal disease patients: a biomarker modifiable by calcium blockade and angiotensin II antagonism? Kidney international vol 70 issue 12 2007 17136131 the nitric oxide synthase inhibitor asymmetric dimethylarginine (adma) is an emerging risk biomarker in cardiovascular and renal diseases. 2007-02-28 2022-01-12 Not clear
Chang-Wu Lu, Yan Xiong, Pei H. Dimethylarginine dimethylaminohydrolase-2 overexpression improves impaired nitric oxide synthesis of endothelial cells induced by glycated protein. Nitric oxide : biology and chemistry vol 16 issue 1 2007 16979918 nitric oxide (no) synthesis is modulated by dimethylarginine dimethylaminohydrolase (ddah) via metabolizing asymmetric dimethylarginine (adma), an endogenous no synthase (nos) inhibitor. 2007-02-27 2022-01-12 Not clear
Claudia Korandji, Marianne Zeller, Jean-Claude Guilland, Catherine Vergely, Pierre Sicard, Laurence Duvillard, Philippe Gambert, Daniel Moreau, Yves Cottin, Luc Rochett. Asymmetric dimethylarginine (ADMA) and hyperhomocysteinemia in patients with acute myocardial infarction. Clinical biochemistry vol 40 issue 1-2 2007 17020756 we sought to investigate the association between increased levels of asymmetric dimethylarginine (adma), an endogenous nitric oxide synthase inhibitor, and total plasma homocysteinemia (thcy) in patients with acute myocardial infarction (ami). 2007-02-26 2022-01-12 Not clear
Edmond O'Riordan, Natalia Mendelev, Susann Patschan, Daniel Patschan, Jonathan Eskander, Leona Cohen-Gould, Praveen Chander, Michael S Goligorsk. Chronic NOS inhibition actuates endothelial-mesenchymal transformation. American journal of physiology. Heart and circulatory physiology vol 292 issue 1 2007 16963618 chronic kidney diseases are accompanied by the accumulation of substances like asymmetric dimethylarginine, phenylacetic acid, homocysteine, and advanced glycation end products, known to either inhibit endothelial nitric oxide synthase (enos) or uncouple it, consequently limiting the amount of available nitric oxide (no). 2007-02-20 2022-01-12 Not clear
Thomas L\\xc3\\xbccke, Dimitrios Tsikas, Nele Kanzelmeyer, Bernhard Vaske, Anibh Martin Da. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in citrullinemia. Metabolism: clinical and experimental vol 55 issue 12 2007 17142130 elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in citrullinemia. 2007-02-20 2022-01-12 Not clear
Thomas L\\xc3\\xbccke, Dimitrios Tsikas, Nele Kanzelmeyer, Bernhard Vaske, Anibh Martin Da. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in citrullinemia. Metabolism: clinical and experimental vol 55 issue 12 2007 17142130 asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase that converts l-arginine to l-citrulline and nitric oxide (no). 2007-02-20 2022-01-12 Not clear
Satoshi Yasuda, Shunichi Miyazaki, Munetake Kanda, Yoichi Goto, Masaaki Suzuki, Yutaka Harano, Hiroshi Nonog. Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. European heart journal vol 27 issue 10 2007 16627554 intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. 2007-02-07 2022-01-12 Not clear
Marta Kalousov\\xc3\\xa1, Jan T Kielstein, Magdal\\xc3\\xa9na Hodkov\\xc3\\xa1, Tom\\xc3\\xa1s Zima, Sylvie Dusilov\\xc3\\xa1-Sulkov\\xc3\\xa1, Jens Martens-Lobenhoffer, Stefanie M Bode-Boge. No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients. Blood purification vol 24 issue 5-6 2007 16940714 it has been suggested that hemodiafiltration (hdf) is more efficient than hemodialysis (hd) in lowering plasma levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (adma), which is a strong and independent predictor of overall mortality in esrd patients. 2007-02-06 2022-01-12 Not clear
J Wang, A S Sim, X L Wang, D E L Wilcke. L-arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic (HepG2) cells. Cellular and molecular life sciences : CMLS vol 63 issue 23 2007 17075694 an increase in circulating asymmetric dimethylarginine (adma) and a decreased l-arginine/adma ratio are associated with reduced endothelial nitric oxide (no) production and increased risk of vascular disease. 2007-02-01 2022-01-12 Not clear
Asife Sahinarslan, Atiye Cengel, Gursel Biberoglu, Alev Hasanoglu, Sedat Turkoglu, Timur Timurkayna. Plasma asymmetric dimethylarginine level and extent of lesion at coronary angiography. Coronary artery disease vol 17 issue 7 2007 17047444 given that the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, can decrease nitric oxide bioavailability and lead to atherosclerosis, its concentration can be a good predictor for coronary artery disease. 2007-01-30 2022-01-12 Not clear
Rajeshwar P Mookerjee, Mohammed Malaki, Nathan A Davies, Stephen J Hodges, R Neil Dalton, Charles Turner, Sambit Sen, Roger Williams, James Leiper, Patrick Vallance, Rajiv Jala. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology (Baltimore, Md.) vol 45 issue 1 2007 17187433 asymmetric dimethylarginine (adma), an endogenous nitric oxide synthase inhibitor, undergoes hepatic metabolism via dimethylarginine-dimethylamino-hydrolase, and is derived by the action of protein-arginine-methyltransferases. 2007-01-23 2022-01-12 Not clear
Katarzyna Krzyzanowska, Friedrich Mittermayer, Walter Krugluger, Christoph Schnack, Martin Hofer, Michael Wolzt, Guntram Schernthane. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis vol 189 issue 1 2007 16414052 the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (adma) and total homocysteine (thcy) are elevated in patients at increased cardiovascular risk. 2007-01-09 2022-01-12 Not clear
Mehmet Sahin, Cagatay Arslan, Mustafa Naziroglu, S Ercan Tunc, Mustafa Demirci, Recep Sutcu, Nigar Yilma. Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet's disease. Annals of clinical and laboratory science vol 36 issue 4 2007 17127734 asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in behcet's disease. 2007-01-09 2022-01-12 Not clear
Mehmet Sahin, Cagatay Arslan, Mustafa Naziroglu, S Ercan Tunc, Mustafa Demirci, Recep Sutcu, Nigar Yilma. Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet's disease. Annals of clinical and laboratory science vol 36 issue 4 2007 17127734 asymmetric dimethylarginine (adma) is an endogenous inhibitor of nitric oxide (no) synthase. 2007-01-09 2022-01-12 Not clear
Kyoko Matsuguma, Seiji Ueda, Sho-ichi Yamagishi, Yuriko Matsumoto, Utako Kaneyuki, Ryo Shibata, Toshiko Fujimura, Hidehiro Matsuoka, Masumi Kimoto, Seiya Kato, Tsutomu Imaizumi, Seiya Okud. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. Journal of the American Society of Nephrology : JASN vol 17 issue 8 2006 16807406 asymmetric dimethylarginine (adma) is an endogenous inhibitor of nitric oxide synthase. 2006-12-14 2022-01-13 Not clear
Friedrich Mittermayer, Katarzyna Krzyzanowska, Markus Exner, Wolfgang Mlekusch, Jasmin Amighi, Schila Sabeti, Erich Minar, Markus M\\xc3\\xbcller, Michael Wolzt, Martin Schillinge. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arteriosclerosis, thrombosis, and vascular biology vol 26 issue 11 2006 16931791 circulating concentrations of asymmetric dimethylarginine (adma), an endogenous inhibitor of nitric oxide synthesis, are elevated in conditions associated with increased cardiovascular risk. 2006-11-13 2022-01-12 Not clear
Ewa Kopieczna-Grzebieniak, Ma\\xc5\\x82gorzata Gos. [The importance of regulation of endogenous methylarginine concentrations in clinical practice]. Przeglad lekarski vol 62 issue 12 2006 16786781 asymmetric dimethylarginine (adma) and n-mono-methylarginine (mma), are competitive inhibitors of nitric oxide synthases. 2006-11-06 2022-01-13 Not clear
Page: 
1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27   28   29   30   31   32   33   34   35   36   37   38   39   40   41   42   43   44   45   46   47   48   49   50   51   52   53   54